{"nctId":"NCT02446717","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","startDateStruct":{"date":"2015-04","type":"ACTUAL"},"conditions":["Chronic Hepatitis C","Hepatitis C Virus","HCV","Direct-Acting Antiviral Agent (DAA)-Experienced"],"count":141,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493, ABT-530"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493, ABT-530","Drug: ribavirin (RBV)"]},{"label":"Arm C","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493, ABT-530"]},{"label":"Arm D","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"Arm E","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]}],"interventions":[{"name":"ABT-493, ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","ABT-493/ABT-530 (ABT-493 coformulated with ABT-267) also known as MAVYRET"]},{"name":"ribavirin (RBV)","otherNames":[]},{"name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients from 18 to 70 years in Arms A, B, and C; patients 18 years of age or older in Arms D and E.\n2. Previous treatment with DAA-containing regimen for chronic hepatitis C virus (HCV) infection resulting in either on-treatment virologic failure or post-treatment relapse\n3. Chronic HCV genotype (GT) 1, 4, 5, or 6-infection (GT4-6 in Arms D and E)\n\nExclusion Criteria:\n\n1. History of severe, life-threatening or other significant sensitivity to any drug\n2. Female who is pregnant, planning to become pregnant during the study or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study\n3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol\n4. Positive for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab)\n5. Co-infection with more than one HCV genotype","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"95.5","spread":null},{"groupId":"OG002","value":"86.4","spread":null},{"groupId":"OG003","value":"88.6","spread":null},{"groupId":"OG004","value":"91.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)","description":"SVR4 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 4 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"95.5","spread":null},{"groupId":"OG002","value":"95.5","spread":null},{"groupId":"OG003","value":"90.9","spread":null},{"groupId":"OG004","value":"91.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed HCV RNA ≥ 100 IU after HCV RNA \\< LLOQ during treatment; confirmed increase of \\> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"4.5","spread":null},{"groupId":"OG003","value":"2.3","spread":null},{"groupId":"OG004","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants with HCV RNA levels \\< LLOQ at the end of treatment, excluding reinfection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"9.3","spread":null},{"groupId":"OG004","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["HEADACHE","FATIGUE","NAUSEA","INSOMNIA","CONSTIPATION"]}}}